Company intelligence / Profile preview
Larimar Therapeutics
Bala Cynwyd, Pennsylvania, United Stateslarimartx.com ↗
- Ownership
- Public · LRMR
- Employees
- ~65
- Development stage
- Other
01
Overview
Larimar’s lead candidate nomlabofusp (formerly CTI–1601) has shown dose-dependent increases in frataxin levels and was generally well tolerated with no serious adverse events in Phase 2 studies. The FDA has selected the program for its START pilot to accelerate development. An open-label extension study continues enrolling, and a global Phase 3 trial will begin mid–2025. The company aims to submit a BLA by year-end 2025 seeking accelerated approval using skin FXN concentration as a surrogate endpoint.
- Therapeutic areas
- Neurology
- Modalities
- Protein replacement therapy (fusion proteins)Cell penetrating peptide technology
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Friedreich’s Ataxia Research Alliance / TRACK–FA Neuroimaging Consortium academic/industry collaboration
04
Financials
- Market cap
- $241M
- Total revenue
- $0
- Enterprise value
- $89.7M
Beyond the preview
Go deeper on Larimar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Larimar Therapeutics.